Carolina Santiago de Araújo Pio1, Susan Marzolini2, Maureen Pakosh2, Sherry L Grace3. 1. York University, School of Kinesiology and Health Science, Toronto, Ontario, Canada. 2. University Health Network-University of Toronto, Toronto, Ontario, Canada. 3. York University, School of Kinesiology and Health Science, Toronto, Ontario, Canada; University Health Network-University of Toronto, Toronto, Ontario, Canada. Electronic address: sgrace@yorku.ca.
Abstract
OBJECTIVE: To ascertain the effect of cardiac rehabilitation (CR) dose (ie, duration × frequency/wk; categorized as low [<12 sessions], medium [12-35 sessions], or high [≥36 sessions]) on mortality and morbidity. METHODS: The Cochrane, CINAHL, EMBASE, PsycINFO, and MEDLINE databases were systematically searched from inception through November 30, 2015. Inclusion criteria included randomized or nonrandomized studies with a minimum CR dose of 4 or higher and presence of a control/comparison group. Citations were considered for inclusion, and data were extracted in included studies independently by 2 investigators. Studies were pooled using random-effects meta-analysis and meta-regression where warranted (covariates included study quality, country, publication year, and diagnosis). RESULTS: Of 4630 unique citations, 33 trials were included comparing CR to usual care (ie, no dose). In meta-regression, greater dose was significantly related to lower all-cause mortality (high: -0.77; SE, 0.22; P<.001; medium: -0.80; SE, 0.21; P<.001) when compared with low dose. With regard to morbidity, meta-analysis revealed that dose was significantly associated with fewer percutaneous coronary interventions (high: relative risk, 0.65; 95% CI, 0.50-0.84; medium/low: relative risk, 1.04; 95% CI, 0.74-1.48; between subgroup difference P=.03). This reduction was also significant in meta-regression (high vs medium/low: -0.73; SE, 0.20; P<.001). Publication bias was not evident. No dose-response association was found for cardiovascular mortality, all-cause hospitalization, coronary artery bypass graft surgery, or myocardial infarction. CONCLUSION: A minimum of 36 CR sessions may be needed to reduce percutaneous coronary interventions. Future studies should examine the effect of actual dose of CR, and trials are needed comparing different doses. PROSPERO REGISTRATION: CRD42016036029.
OBJECTIVE: To ascertain the effect of cardiac rehabilitation (CR) dose (ie, duration × frequency/wk; categorized as low [<12 sessions], medium [12-35 sessions], or high [≥36 sessions]) on mortality and morbidity. METHODS: The Cochrane, CINAHL, EMBASE, PsycINFO, and MEDLINE databases were systematically searched from inception through November 30, 2015. Inclusion criteria included randomized or nonrandomized studies with a minimum CR dose of 4 or higher and presence of a control/comparison group. Citations were considered for inclusion, and data were extracted in included studies independently by 2 investigators. Studies were pooled using random-effects meta-analysis and meta-regression where warranted (covariates included study quality, country, publication year, and diagnosis). RESULTS: Of 4630 unique citations, 33 trials were included comparing CR to usual care (ie, no dose). In meta-regression, greater dose was significantly related to lower all-cause mortality (high: -0.77; SE, 0.22; P<.001; medium: -0.80; SE, 0.21; P<.001) when compared with low dose. With regard to morbidity, meta-analysis revealed that dose was significantly associated with fewer percutaneous coronary interventions (high: relative risk, 0.65; 95% CI, 0.50-0.84; medium/low: relative risk, 1.04; 95% CI, 0.74-1.48; between subgroup difference P=.03). This reduction was also significant in meta-regression (high vs medium/low: -0.73; SE, 0.20; P<.001). Publication bias was not evident. No dose-response association was found for cardiovascular mortality, all-cause hospitalization, coronary artery bypass graft surgery, or myocardial infarction. CONCLUSION: A minimum of 36 CR sessions may be needed to reduce percutaneous coronary interventions. Future studies should examine the effect of actual dose of CR, and trials are needed comparing different doses. PROSPERO REGISTRATION: CRD42016036029.
Authors: Michel Farah; Maya Abdallah; Heidi Szalai; Robert Berry; Tara Lagu; Peter K Lindenauer; Quinn R Pack Journal: Mayo Clin Proc Date: 2019-12 Impact factor: 7.616
Authors: Raquel Rodrigues Britto; Marta Supervia; Karam Turk-Adawi; Gabriela Suéllen da Silva Chaves; Ella Pesah; Francisco Lopez-Jimenez; Danielle Aparecida Gomes Pereira; Artur H Herdy; Sherry L Grace Journal: Braz J Phys Ther Date: 2019-03-05 Impact factor: 3.377
Authors: Quinn R Pack; Paul Visintainer; Michel Farah; Grace LaValley; Heidi Szalai; Peter K Lindenauer; Tara Lagu Journal: J Cardiopulm Rehabil Prev Date: 2021-05-01 Impact factor: 2.081
Authors: Shanshan Li; Gregg C Fonarow; Kenneth Mukamal; Haolin Xu; Roland A Matsouaka; Adam D Devore; Deepak L Bhatt Journal: J Am Heart Assoc Date: 2018-04-06 Impact factor: 5.501
Authors: Gabriela Lima de Melo Ghisi; Ella Pesah; Karam Turk-Adawi; Marta Supervia; Francisco Lopez Jimenez; Sherry L Grace Journal: J Clin Med Date: 2018-09-07 Impact factor: 4.241